BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Xenograft Model Antitumor Assays

Below is an extended Xenograft Model Antitumor Assays research listing. Click here to return to the Xenograft Model Antitumor Assays main in depth entry.

Recent Publications on Xenograft Model Antitumor Assays:

T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling.
BACKGROUND: Prostate cancer (PC) is the most common cancer among men in...
Direct Link
6th September, 2008
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030,
Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.
PURPOSE: To assess the effects of noscapine, a tubulin-binding drug, in...
Direct Link
5th September, 2008
Department of Pathology, New York University School of Medicine, 550 First
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
The discovery of new small molecules and their testing in rational...
Direct Link
4th September, 2008
Department of Pediatric Oncology, Dana-Farber Cancer Institute and
Nanoparticle-mediated gene delivery to the lung.
Drug delivery, especially gene delivery to the lung, has been a challenge....
Direct Link
30th August, 2008
Department of Thoracic and Cardiovascular Surgery, The University of Texas
Target specificity of 188Re-labeled B27.1 monoclonal antibodies to ovarian cancer cells in vivo. 30th August, 2008
Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.
4-(1,3-Thiazol-2-yl)morpholine derivatives have been identified as potent...
Direct Link
23rd August, 2008
Department of Medicinal Chemistry, UCB, 208 Bath Road, Slough, Berkshire
Caspase-3 enhances lung metastasis and cell migration in a protease-independent mechanism through the ERK pathway.
Caspase-3 is known as a cysteine protease that primarily executes the cell...
Direct Link
23rd August, 2008
Department of Microbiology and Immunology, National Cheng Kung University,
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been...
Direct Link
23rd August, 2008
Cancer and Infection Research Area, AstraZeneca Pharmaceuticals, Alderley
Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor.
Angiogenesis plays a key role in the development of a wide variety of...
Direct Link
22nd August, 2008
Institute of Biochemistry and Cell Biology, Shanghai Institutes for
Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.
Umbilical cord matrix stem (UCMS) cells that were engineered to express...
Direct Link
15th August, 2008
Department of Anatomy & Physiology, Kansas State University, Manhattan,
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.
Integrin alphanubeta3 is found on a subset of tumor blood vessels where it...
Direct Link
9th August, 2008
Department of Pathology, Moores Cancer Center, University of California at
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. 26th July, 2008
Department of Surgery, Fujita Health University School of Medicine,
Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. 26th July, 2008
Department of Orthopaedic Surgery, Graduate School of Medical Sciences,
The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. 26th July, 2008
Department of Medical Cell Biology, Children's Hospital, Uppsala
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. 26th July, 2008
Endocrinology and Metabolic Medicine and Sterix Ltd., Faculty of Medicine,
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional